

FIG. 2. Vif is a positive and negative regulator of viral infectivity. **A**, schematic representation of the experimental procedure. H9 cells are non-permissive and do not support replication of Vif-defective viruses. LuSIV cells are CD4⁺ indicator cells carrying a luciferase gene under the control of the SIV_{mac259} long terminal repeat (33). **B**, H9 cells were electroporated with constant amounts (5 µg) each of the Vif- and Env-defective pNL43-K1.vif(-) proviral construct and the VSV-G expression vector, pHCMV-G. In addition, increasing amounts of the Vif expression vector pNL-A1 (0–10 µg) were included as indicated at the bottom. All samples were adjusted to a total of 20 µg of plasmid DNA using the Vif-defective variant pNL-A1.vif(-). Transfected cells and virus-containing supernatants were harvested 24 h after electroporation, and cell lysates were subjected to immunoblot analysis using a Vif-specific antiserum (α -Vif) or an HIV-positive patient serum (APS). Proteins are identified on the left. Virus-containing supernatants were adjusted for equal reverse transcriptase activity (46) and used for the infection of LuSIV indicator cells. Luciferase activity was determined 24 h after infection and used to calculate the relative infectivity of the individual virus stocks (top). Maximal infectivity was defined as 100%.

APOBEC3G. Quantitation of the Vif-specific bands (Fig. 1B) revealed no differences in the relative decay rates of Vif. Thus, expression of APOBEC3G had no impact on the intracellular stability of Vif. The intracellular site of Vif degradation is under investigation; however, preliminary data suggest the involvement of the cellular proteasome machinery (35).²

High Level Expression of Vif in Virus-producing Cells Is Determinantal to HIV-1 Infectivity.—The rapid intracellular turnover presumably contributes to the low abundance of Vif in virus-infected cells and limits its packaging into virions. This suggests that Vif may function at very low levels. To determine how much Vif is required for maximal viral infectivity, we examined the dose-dependent effect of Vif on viral infectivity in non-permissive H9 cells. Virus stocks were produced in the presence of increasing amounts of Vif and tested for infectivity in a single-round infection assay. To avoid subsequent rounds of infection, an env-defective proviral construct, pNL43-K1.vif(-), was used and pseudotyped with VSV-G. As pNL43-K1.vif(-) is also defective in its vif gene, Vif was expressed in *trans* from pNL-A1 (30). This allowed for the controlled expression of increasing amounts of Vif depending on the amounts of pNL-A1 vector transfected. To avoid fluctuations in transfection efficiencies all DNA amounts were equalized by addition of appropriate amounts of a Vif-

defective variant of pNL-A1, pNL-A1.vif(-). Cells transfected with constant amounts (5 µg) of pNL43-K1.vif(-) as well as pHCMV-G (5 µg) and increasing amounts of pNL-A1 (0.01–10 µg) were harvested 24 h after electroporation. Cell lysates and virus-containing supernatants were used for biochemical characterization as well as for the infection of LuSIV indicator cells as illustrated in Fig. 2A. LuSIV cells were collected 24 h after infection, and luciferase activity in the cell lysates was measured as described under "Experimental Procedures." Luciferase activity was normalized for input virus and expressed as percentage of the activity observed for a Vif-expressing control virus, which was defined as 100% (Fig. 2B). At low expression levels, Vif enhanced virus infectivity in a dose-dependent manner reaching a peak of infectivity at 1 µg of cotransfected pNL-A1 plasmid DNA. Surprisingly, however, viral infectivity did not plateau with further increases in Vif, but instead higher levels of Vif resulted in a rapid drop in virus infectivity. In fact, at the highest concentration tested (10 µg of pNL-A1 plasmid), the infectivity of the resulting virus was comparable with that of Vif-defective virus. Western blot analysis confirmed that the levels of Vif expression were directly correlated with the amounts of pNL-A1 plasmid transfected (Fig. 2B, α -Vif) and that increasing Vif expression did not significantly affect Gag expression (Fig. 2B, APS). These results demonstrate that the level of Vif required for maximal infectivity has a very narrow optimum and that both

² M. Fujita, manuscript in preparation.




Fig. 3. Inhibition of virus infectivity at high levels of Vif is cell type-independent. *A* and *B*, H9 cells were electroporated with increasing amounts (1, 3, or 10 μ g) of the Vif-expressing pNL-A1 plasmid DNA, together with a proviral construct and pHCMV-G, essentially as described for Fig. 1. In *A* the Vif- and Env-defective proviral vector pNL43-K1.vif(-) was employed, whereas in *B* a Vif-expressing variant, pNL43-K1, was used. *C* and *D*, HeLa cells were transfected following the same schedule as described for *A* and *B* except that the total amount of DNA was adjusted to 5 μ g. The relative ratio of individual plasmids was not changed. Virus-containing supernatants were harvested for all samples 24 h after transfection, normalized for equal reverse transcriptase activity, and used for the infection of LuSIV cells. Viral infectivity was calculated as described for Fig. 1. In all four sets, a Vif-deficient control (first bar in each panel) and a positive control expressing physiological amounts of Vif (second bar) were included. The dotted line indicates 50% infectivity.

lower and higher levels of Vif are detrimental to virus infectivity.

Inhibition of Virus Infectivity at High Levels of Vif Is Cell Type-independent.—The results from Fig. 2 are unexpected inasmuch as they are inconsistent with a model that simply envisions a role of Vif in the inactivation of cellular inhibitor(s) such as APOBEC3G. To directly examine the requirement of cellular inhibitory factors for the dose-dependent effect of Vif on viral infectivity, we compared the infectivity of virus stocks produced from non-permissive H9 cells and permissive HeLa cells in the presence of increasing amounts of Vif. In addition, to rule out the possibility that the inhibitory effect of Vif seen following overexpression in *trans* is due to the fact that the proviral vector employed in this study carried a defective *vif* gene, we analyzed a Vif-expressing variant (pNL43-K1) in direct comparison to the Vif-defective pNL43-K1.vif(-). H9 cells (Fig. 3, *A* and *B*) and HeLa cells (*C* and *D*) were transfected with increasing amounts (1–10 μ g) of pNL-A1 together with fixed amounts (5 μ g) of pNL43-K1 or pNL43-K1.vif(-) as indi-

cated in Fig. 3. In addition, a fixed amount (5 μ g) of pHCMV-G was included to produce VSV-G-pseudotyped virus stocks. As before, DNA quantities were adjusted to 20 μ g in all samples using appropriate amounts of pNL-A1.vif(-) plasmid DNA. Consistent with the results from Fig. 2, physiological levels of Vif supplied in *trans* or in *cis* produced fully infectious virus from both H9 and HeLa cells, and further increase in the amounts of Vif progressively reduced viral infectivity in H9-derived virus (Fig. 3, *A* and *B*). Interestingly, the inhibitory effect of Vif expressed in *cis* and in *trans* appeared to be additive because in the presence of endogenous Vif, smaller amounts of exogenous Vif were necessary for a comparable degree of inhibition (compare *A* and *B* of Fig. 3). These results indicate that the inhibitory effect of high levels of Vif on virus infectivity in Fig. 2 was not due to the lack of a functional *vif* gene.

Surprisingly, very similar results were observed when virus was produced from permissive HeLa cells (Fig. 3, *C* and *D*);




FIG. 4. High level expression of Vif in H9-derived virus preparations reveals an effect of Vif on Gag maturation that is evident by the appearance of 33- and 34-kDa Gag intermediates. H9 cells were cotransfected with equal amounts of pNL43-K1.vif(-) and pNL-A1.vif(-) (lanes 1), pNL43-K1 and pNL-A1.vif(-) (lanes 2), or pNL43-K1 and pNL-A1 (lanes 3). Cell lysates (A) and viral pellets (B) obtained 24 h after transfection were analyzed for viral proteins by immunoblotting using an HIV-positive patient serum (APS) or antibodies against Vif (α -Vif), capsid (α -CA), nucleocapsid (α -NC), matrix (α -MA), and reverse transcriptase (α -RT) as indicated. Relative Vif expression levels are marked at the top of each panel. Asterisks mark the positions of the p33/34 Gag intermediates.

overexpression of Vif in *trans* reduced viral infectivity irrespective of the presence or absence of endogenous Vif. Again, endogenous Vif appeared to have an additive effect suggesting a similar molecular mechanism in both cell types. The fact that high level expression of Vif affected viral infectivity in the absence of cellular inhibitory factors suggests that this effect of Vif is unrelated to the noted inhibition of APOBEC3G and thus reflects a separate activity of Vif.

Vif Modulates Gag Processing during Virus Maturation—To investigate the molecular basis of the Vif-induced inhibition of viral infectivity, we performed a biochemical characterization of virions produced in the presence of varying amounts of Vif. The goal was to identify possible effects of Vif on Gag precursor processing or other effects on the viral protein composition that might explain the altered infectivity. In H9 cells, comparable expression and processing of viral proteins including Pr55^{gag} and CA were detected intracellularly using an HIV-positive patient serum (Fig. 4A, APS) irrespective of the level of Vif expression (Fig. 4A, α -Vif). Interestingly, analysis of virus-associated proteins revealed two protein bands of ~33 and 34 kDa, respectively, that were apparent only in viruses produced in the presence of high levels of Vif (Fig. 4B, APS). Both proteins were also recognized by capsid- (Fig. 4B, α -CA) and nucleocapsid-specific (Fig. 4B, α -NC) antisera but not by a matrix-specific antibody (Fig. 4B, α -MA). The reactivity of p33/34 with CA- and NC-specific antibodies identified these proteins as Gag-processing intermediates composed of CA-p2-NC (p33) or CA-p2-NC-p1 (p34). The p33/34 intermediates were significantly less abundant than mature CA or NC suggesting that they represent a minor component of the virions. Importantly, processing of neither p66/p51 reverse transcriptase nor p17 MA was affected by the high levels of Vif (Fig. 4B), indicating that Vif does not act as a general PR inhibitor. In addition, similar Gag-processing intermediates were observed in virus derived from permissive HeLa cells in the presence of high levels of Vif (see Fig. 5). Together, the results




FIG. 5. Vif and 33- and 34-kDa Gag intermediates copurify with the viral nucleoprotein complex. HeLa cells were cotransfected with pNL4-3.vif(-) and pNL-A1.vif(-) (Vif(-)) or pNL4-3.vif(-) and pNL-A1 (Vif(+)). Virus-containing supernatants were concentrated, adjusted to a final concentration of 0.1% Triton X-100, and subjected to sucrose step gradient centrifugation. Three equal fractions were collected as indicated in the diagram. Each fraction was analyzed for viral proteins by immunoblotting using an HIV-positive patient serum (APS) or antibodies to NC (α -NC) and Vif (α -Vif). Asterisks indicate the positions of p33/34.

from this experiment demonstrate that Vif modulates Gag processing to produce CA-p2-NC intermediates.

Vif and Gag Intermediates Associate with the Nucleoprotein Complex—Our observation that Vif modulates the maturation of Gag precursor molecules without acting as a general PR inhibitor suggests that Vif might inhibit Gag processing through steric interference. It is likely that such interference is caused by a direct interaction of Vif with the Gag precursor at or near the p2/NC cleavage site. In fact, several previous stud-




Fig. 6. Effect of in-frame deletions on the ability of Vif to modulate maturation of Gag precursor molecules. *A*, schematic diagram of Vif deletion mutants employed in this experiment. The amino acid regions deleted are shown on the right. *wt*, wild type. *B*, HeLa cells were cotransfected with equal amounts of pNL43-K1.vif(-) and pNL-A1.vif(-) (lane 1), pNL43-K1 and pNL-A1.vif(-) (lane 2), pNL43-K1 and pNL-A1 (lane 3), or pNL43-K1 and various pNL-A1-based Vif deletion mutants as indicated (lanes 4-6). Cell lysates (Cell) and concentrated virus preparations (Virus) were harvested 24 h after transfection and analyzed for viral proteins by immunoblotting using APS, anti-Vif, or anti-NC antibodies as indicated on the right. Viral proteins are identified on the left. Asterisks indicate the positions of p33/34. *C*, virus-containing supernatants from *B* were adjusted for equal reverse transcriptase activities and used for the infection of LuSIV indicator cells. Luciferase activity was determined as described under "Experimental Procedures," and the relative infectivity of the virus stocks was calculated.

ies have demonstrated direct interaction of Vif with the viral Gag precursor molecules *in vitro* (36-38). In addition, our recent observation that mutations in the NC zinc finger domains abolish Vif packaging further points to an interaction of Vif and NC (23). Also, virus-associated Vif is stably associated with the viral core, whereas major portions of the mature CA and NC are sensitive to detergent extraction and thus are either not or only loosely associated with the core (23). If maturation of Gag is blocked through steric interference by Vif, we would assume that the resulting intermediates colocalize with Vif in the viral core. To address this issue, viruses obtained from HeLa cells expressing high levels of Vif (Fig. 5, Vif(+)) or lacking Vif expression (Fig. 5, Vif(-)) were subjected to step gradient centrifugation in the presence of Triton X-100 as reported previously (23). Western blot analysis of individual fractions of the step gradient confirmed the stable association of Vif with the viral core in the insoluble fraction (Fig. 5, lane 3, α -Vif) as well as the presence of MA and major portions of CA and NC in the soluble fraction (Fig. 5, lanes 1). Interestingly, the p33/34 Gag intermediates were resistant to detergent extraction and colocalized with Vif in the viral core fraction (Fig. 5, lane 3, asterisks) in the presence of Vif. These findings indicate that unlike mature CA and NC products, the Gag p33/34 intermediates are tightly associated with the viral nucleoprotein complex, which also contains the viral genomic RNA, reverse transcriptase, integrase, residual Pr55^{Gag}, and Vif (23).

Modulation of Gag Processing Requires Packaging of Vif and Involves N-terminal Regions in Vif—In an attempt to determine the domain(s) in Vif contributing to the modulation of proteolytic processing of the Gag precursor molecules, a series of Vif deletion mutants (schematically diagrammed in Fig. 6A) was evaluated. As can be seen in Fig. 6B, comparable amounts of the wild type and mutant Vif proteins were expressed intracellularly (Fig. 6B, Cell), indicating that the mutations did not affect steady-state levels of the resulting proteins. All Vif variants were packaged into virions at levels comparable with those of wild type virus (Fig. 6B, Virus, α -Vif). No aberrant Gag intermediates were apparent in the absence of Vif (Fig. 6B, lane 1, APS) or in the presence of physiological levels of Vif (lane 2, APS and α -NC). In contrast, high level expression of wild type Vif resulted in the appearance of the p33/34 intermediates (Fig. 6B, lane 3, APS and α -NC; marked by asterisks). Deletion of residues 23-43 in Vif did not impair the ability of Vif to modulate Gag processing as shown by the presence of p33/34 at levels comparable with those observed in the presence of wild type Vif (Fig. 6B, compare lanes 3 and 5, Virus, APS and α -NC). However, deletion of residues 4-45 (Fig. 6B, lane 4) completely abolished the ability of Vif to modulate Gag processing despite the presence of high levels of this Vif variant in the virus preparation. Finally, deletion of residues 23-74 (Fig. 6B, lane 6) partially inhibited the ability to modulate Gag maturation. We confirmed that none of these deletions affected the ability of Vif to associate with the nucleoprotein complex

(data not shown). Analysis of viral infectivity revealed an inverse correlation with the amounts of p33/34 detectable in the virus preparations (Fig. 6C). In contrast, there was no correlation between inhibition of viral infectivity and packaging of Vif. All Vif variants were expressed at similar levels and were packaged and associated with the viral nucleoprotein complex with similar efficiency. Taken together, these results support the notion that inhibition of virus infectivity is correlated with the presence of p33/34 Gag intermediates rather than with the amounts of Vif packaged. Our data further demonstrate that sequences in the N-terminal domain of Vif, in particular residues 4–22, are critical for the ability of Vif to inhibit Gag processing at the p2/NC site.

DISCUSSION

Despite the recent identification of a cellular factor whose inhibitory activity must be overcome by Vif to allow for the production of infectious viruses from non-permissive cell types (10), the molecular mechanism of Vif function and its site(s) of action have remained unclear. We now report for the first time on an activity of Vif that requires its presence in virus particles. Our data suggest that Vif modulates the maturation of a small number of Gag and/or Gag-Pol precursor molecules by physically interacting with the Gag or Gag-Pol precursor at or near the primary cleavage site. Such interaction causes the inhibition of or the delay in processing of Gag at the p2/NC cleavage site resulting in the accumulation of small amounts of p33/34 Gag-processing intermediates. Based on their reactivity with both CA- and NC-specific antibodies the p33/34 intermediates were identified as proteins consisting of CA, NC, and one or both of the spacer peptides p1 and p2. Vif did not affect processing at other proteolytic cleavage sites, suggesting that it selectively blocks processing at the CA-NC boundary through steric interference. It is interesting to note that Vif itself is a substrate for proteolytic processing (24), and it is possible that Vif blocks processing of Gag by acting as a decoy for the viral protease.

Processing of the Gag precursor occurs at five different sites to produce at least six mature processing products (39). This process is highly ordered and starts with an initial cleavage at the p2/NC boundary (40). The resulting processing intermediates are then further processed but at a much reduced rate (41). Inhibition of processing at any of the cleavage sites results in the production of non-infectious virions (41, 42). On the other hand, immunoblot analyses of normal infectious HIV-1 virions invariably identify a series of processing intermediates (see Figs. 2 and 6, *Viruses*, APS; and 4, α -CA) that suggest that Gag processing is incomplete. Notably, most virus preparations contain residual uncleaved Pr55^{gag} precursor. In fact, we noted previously that unlike most mature Gag products, Pr55^{gag} is stably associated with the viral nucleoprotein complex (23). Thus, it is apparent that mature viral particles are composed not only of fully processed Gag and Gag-Pol products but contain residual amounts of Gag precursors and processing intermediates. Whether these processing intermediates have functional significance or are merely signs of an inefficient maturation process remains to be established. However, the noted affinity of Pr55^{gag} as well as the p33/34 intermediates with the viral nucleoprotein complex could imply a role in its formation and/or stabilization.

Vif is known to enhance viral infectivity in a cell type-dependent manner. This phenomenon was recently attributed to the activity of the cellular cytidine deaminase APOBEC3G (13–17). APOBEC3G is packaged into HIV particles where it induces hypermutation of the minus-strand cDNA (10, 14–17). This inhibitory effect of APOBEC3G is counteracted by Vif, which interferes with the packaging of APOBEC3G. How Vif inhibits packaging of APOBEC3G is still under investigation;

however, it appears to involve in part a reduction of the intracellular protein levels through proteasome-dependent degradation (18, 20, 21, 25, 35, 43) and requires a physical interaction between the two proteins (17, 18, 21, 35). Thus, like all other viral accessory proteins, Vif appears to be a multifunctional adapter molecule with seemingly opposing effects; binding of Vif to APOBEC3G appears to accelerate its intracellular turnover, whereas the interaction of Vif with the Gag precursor in virions inhibits its proteolytic processing. It is currently unclear whether the domains in Vif required for interaction with APOBEC3G and Gag are the same or map to different regions in the protein. The results from our current study (Fig. 6) suggest that inhibition of Gag processing involves an N-terminal domain in Vif. Although these same mutants were found to also be inactive with respect to APOBEC3G (19), other Vif mutants such as Vif Δ 23–43 were inactive against APOBEC3G (19) but still inhibited Gag maturation. These results combined with the fact that the effect of Vif on the proteolytic processing of Gag precursors is cell type-independent suggest that the effect of Vif on Gag maturation is mechanistically independent of its neutralization of APOBEC3G. It remains to be investigated whether the interaction of Vif with Gag precursor molecules during or following virus assembly relates to its ability to inhibit packaging of APOBEC3G. This seems possible as the reported reduction of intracellular expression levels of APOBEC3G by Vif does not fully account for the noted exclusion of APOBEC3G from virus particles (17, 19).

The fact that high level expression of Vif is detrimental to viral infectivity confirms that Gag maturation is a carefully balanced process. Thus, rapid degradation of Vif in virus-producing cells may have evolved as a mechanism to preclude the detrimental effects on Gag maturation. Our observation that the accumulation of the CA-p2-NC intermediates is directly correlated with the levels of Vif expression (data not shown) leads us to conclude that similar processing intermediates are produced under physiological conditions but are below the limit of detection in our assay system. The fact that packaging of large quantities of Vif N-terminal deletion mutants did not affect Gag maturation (Fig. 6) suggests that the effect of Vif is specific albeit only detectable by currently available immunoblotting techniques at high levels of Vif. Thus, it is possible that minute quantities of CA-p2-NC- and CA-p2-NC-p1-processing intermediates play an important role in viral infectivity. The fact that such intermediates, unlike their mature products, are stably associated with the nucleoprotein complex raises the possibility that the association of these intermediates with Vif and viral genomic RNA promotes the stability or proper conformation of the viral nucleoprotein complex. Such a function would be consistent with previous reports correlating the lack of Vif with a reduced stability of nucleoprotein complexes (8, 44, 45).

Acknowledgments—We thank Stephan Bour and Eri Miyagi for helpful discussions and Eric Freed for critical comments on the manuscript. We thank Alicia Buckler-White and Ron Plishka for oligonucleotide synthesis and sequence analysis. We acknowledge Mary Karczewski and Claudia Aberham for construction of the Vif mutants and Robert Gorelick, Susan Zolla-Pazner, and Paul Spearman for antibodies. Antibodies to CA and MA were obtained through the National Institutes of Health AIDS Research and Reference Reagent Program.

REFERENCES

1. Bour, S., and Strobel, K. (2000) *Adv. Pharmacol.* 48, 75–120
2. Cullen, B. R. (1998) *Cell* 93, 685–692
3. Akari, H., Uchiyama, T., Fukumori, T., Iida, S., Koyama, A. H., and Adachi, A. (1999) *J. Gen. Virol.* 80, 2945–2949
4. Chowdhury, I. H., Chao, W., Polash, M. J., Sova, P., Gendelman, H. E., and Volsky, D. J. (1999) *J. Virol.* 70, 5336–5345
5. Courroul, M., Patience, C., Roy, F., Blanc, D., Harmache, A., Sire, J., Vigne, R., and Spire, B. (1995) *J. Virol.* 69, 2068–2074
6. Goncalves, J., Korin, Y., Zack, J., and Gabuzda, D. (1996) *J. Virol.* 70,

- 8701-8709
7. Reddy, T. R., Kraus, G., Yamada, O., Looney, D. J., Suhasini, M., and Wong-Staal, F. (1995) *J. Virol.* **69**, 3549-3555
 8. Simon, J. H., and Malim, M. H. (1996) *J. Virol.* **70**, 5297-5305
 9. von Schwedler, U., Song, J., Aiken, C., and Trono, D. (1993) *J. Virol.* **67**, 4945-4955
 10. Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002) *Nature* **418**, 646-650
 11. Madani, N., and Kabat, D. (1998) *J. Virol.* **72**, 10251-10255
 12. Simon, J. H., Gaddis, N. C., Fouchier, R. A., and Malim, M. H. (1998) *Nat. Med.* **4**, 1397-1400
 13. Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. K., Watt, I. N., Neuberger, M. S., and Malim, M. H. (2003) *Cell* **113**, 805-809
 14. Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C., and Gao, L. (2003) *Nature* **424**, 94-96
 15. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003) *Nature* **424**, 99-103
 16. Lacossier, D., Bouchonnet, F., Clavel, F., and Hance, A. J. (2003) *Science* **300**, 1112
 17. Mariotti, R., Chen, D., Schrofelbauer, B., Navarro, F., Konig, R., Bollman, B., Munk, C., Nymark-McMahon, H., and Landau, N. R. (2008) *Cell* **114**, 21-31
 18. Stupak, K., de Noronha, C., Yonemoto, W., and Greene, W. C. (2003) *Mol. Cell* **12**, 591-601
 19. Kao, S., Khan, M. A., Miyagi, E., Pishko, R., Buckler-White, A., and Strebel, K. (2003) *J. Virol.* **77**, 11398-11407
 20. Sheehy, A. M., Gaddis, N. C., and Malim, M. H. (2003) *Nat. Med.* **9**, 1404-1407
 21. Marin, M., Rose, K. M., Kozak, S. L., and Kabat, D. (2003) *Nat. Med.* **9**, 1388-1403
 22. Kao, S., Akari, H., Khan, M. A., Dettienhofer, M., Yu, X. F., and Strebel, K. (2003) *J. Virol.* **77**, 1131-1140
 23. Khan, M. A., Aberham, C., Kao, S., Akari, H., Gorelick, R., Bour, S., and Strebel, K. (2001) *J. Virol.* **75**, 7252-7265
 24. Khan, M. A., Akari, H., Kao, S., Aberham, C., Davis, D., Buckler-White, A., and Strebel, K. (2002) *J. Virol.* **76**, 9112-9123
 25. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Miao, P., and Yu, X. F. (2003) *Science* **302**, 1058-1060
 26. Adachi, A., Gondelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., and Martin, M. A. (1986) *J. Virol.* **58**, 284-291
 27. Bour, S., and Strebel, K. (1996) *J. Virol.* **70**, 8285-8300
 28. Karczewski, M. K., and Strebel, K. (1996) *J. Virol.* **70**, 494-507
 29. Yeo, J. K., Miyahara, A., LaPorte, P., Bouic, K., Burns, J. C., and Friedmann, T. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91**, 9564-9568
 30. Strebel, K., Daugherty, D., Clouse, K., Cohen, D., Folks, T., and Martin, M. A. (1987) *Nature* **328**, 728-730
 31. Gorny, M. K., Gianakakos, V., Sbarbo, S., and Zolla-Pazner, S. (1989) *Proc. Natl. Acad. Sci. U. S. A.* **86**, 1624-1628
 32. Varthakavi, V., Browning, P. J., and Spearman, P. (1999) *J. Virol.* **73**, 10329-10338
 33. Roos, J. W., Maughan, M. F., Liao, Z., Hildreth, J. E., and Clements, J. E. (2000) *Virology* **273**, 307-315
 34. Aiken, C. (1997) *J. Virol.* **71**, 5871-5877
 35. Mehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M., and Gabuzda, D. (2004) *J. Biol. Chem.* **279**, 7792-7798
 36. Bardy, M., Gay, B., Pebernard, S., Chazal, N., Courcou, M., Vigne, R., Deroly, E., and Boulanger, P. (2001) *J. Gen. Virol.* **82**, 2719-2733
 37. Bouyac, M., Courcou, M., Bertoia, G., Boudat, Y., Gabuzda, D., Blanc, D., Chazal, N., Boulanger, P., Sire, J., Vigne, R., and Spiro, B. (1997) *J. Virol.* **71**, 9358-9365
 38. Huvent, I., Hong, S. S., Fournier, C., Gay, B., Tournier, J., Carriere, C., Courcou, M., Vigne, R., Spiro, B., and Boulanger, P. (1998) *J. Gen. Virol.* **79**, 1069-1081
 39. Henderson, L. E., Sowder, R. C., Copeland, T. D., Oroszlan, S., and Benveniste, R. E. (1990) *J. Med. Primatol.* **19**, 411-419
 40. Erickson-Viitanen, S., Manfredi, J., Viitanen, P., Tribe, D. E., Tritch, R., Hutchison, C. A., III, Leeb, D. D., and Swanstrom, R. (1989) *AIDS Res. Hum. Retroviruses* **5**, 577-591
 41. Pettit, S. C., Moody, M. D., Wehble, R. S., Kaplan, A. H., Nantmet, P. V., Klein, C. A., and Swanstrom, R. (1994) *J. Virol.* **68**, 3017-3027
 42. Wieggers, K., Rutter, G., Kottler, H., Tessmer, U., Hohenberg, H., and Krauslich, H. G. (1993) *J. Virol.* **72**, 2846-2854
 43. Conticello, S. G., Harris, R. S., and Neuberger, M. S. (2003) *Curr. Biol.* **13**, 2009-2013
 44. Ohagen, A., and Gabuzda, D. (2000) *J. Virol.* **74**, 11055-11066
 45. Haglund, S., Ohagen, A., Lawrence, K., and Gabuzda, D. (1994) *Virology* **201**, 349-355
 46. Willey, R. L., Smith, D. H., Lasky, L. A., Theodore, T. S., Earl, P. L., Moss, B., Capon, D. J., and Martin, M. A. (1988) *J. Virol.* **62**, 139-147

Paramyxovirus Sendai virus-like particle formation by expression of multiple viral proteins and acceleration of its release by C protein

Fumihiro Sugahara,^a Tsuneo Uchiyama,^b Hitoshi Watanabe,^a Yukie Shimazu,^a Masaru Kuwayama,^a Yutaka Fujii,^a Katsuhiko Kiyotani,^a Akio Adachi,^b Nobuoki Kohno,^c Tetsuya Yoshida,^a and Takemasa Sakaguchi^{a,*}

^a Department of Virology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan

^b Department of Virology, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan

^c Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan

Received 17 February 2004; returned to author for revision 22 March 2004; accepted 10 April 2004

Abstract

Envelope viruses mature by macromolecule assembly and budding. To investigate these steps, we generated virus-like particles (VLPs) by co-expression of structural proteins of Sendai virus (SeV), a prototype of the family Paramyxoviridae. Simultaneous expression of matrix (M), nucleocapsid (N), fusion (F), and hemagglutinin-neuraminidase (HN) proteins resulted in the generation of VLPs that had morphology and density similar to those of authentic virus particles, although the efficiency of release from cells was significantly lower than that of the virus. By using this VLP formation as a model of virus budding, roles of individual proteins in budding were investigated. The M protein was a driving force of budding, and the F protein facilitated and the HN protein suppressed VLP release. Either of the glycoproteins, F or HN, as well as the N protein, significantly shifted density of VLPs to that of virus particles, suggesting that viral proteins bring about integrity of VLPs by protein–protein interactions. We further found that co-expression of a nonstructural protein, C, but not V, enhanced VLP release to a level comparable to that of virus particles, demonstrating that the C protein plays a role in virus budding.

© 2004 Elsevier Inc. All rights reserved.

Keywords: Sendai virus; Virus-like particle; Morphology; Density; Nucleocapsid; C protein

Introduction

Sendai virus (SeV), a prototype of the family Paramyxoviridae, is an enveloped virus with a nonsegmented negative-strand RNA genome. The SeV virion has two spike glycoproteins on the lipid-containing envelope, the hemagglutinin-neuraminidase (HN) protein and the fusion (F) protein. Lying underneath the envelope is the matrix (M) protein, which bridges the viral glycoproteins and the internal nucleocapsid. The nucleocapsid has a helical structure consisting of genomic RNA enwrapped with the nucleocapsid (N) protein, associated with RNA polymerase subunits, the large (L) protein, and the phosphoprotein (P). Besides these structural proteins, the P gene encodes the C proteins and the V protein. The C proteins are a generic name of four proteins, C', C, Y1, and Y2, formed by the various start

codons and the common stop codon in a reading frame shifted from that of the P protein. The V protein is synthesized from an accessory mRNA generated by RNA editing during transcription and containing an insertion of a pseudotemplated G residue at a specific editing site. These proteins are not basically incorporated into virions and are termed nonstructural proteins (Lamb and Kolakofsky, 2001; Nagai, 1999). SeV replicates in the cytoplasm and is released from infected cells by assembly and budding at the plasma membrane. Although the current model for assembly of the paramyxovirus implicates the M protein as the principal component promoting the budding of the virus particle (Peeples, 1991; Yoshida et al., 1976, 1979), the underlying mechanism of virion formation is still poorly understood.

Previous studies on retroviruses using the virus-like particle (VLP) system have made great progress in identification of functional domains for budding in the gag protein and in elucidation of their budding mechanisms (Accola et al., 2000; reviewed in Freed, 2002). In the VLP system, the

* Corresponding author. Fax: +81-82-257-5159.

E-mail address: tsaka@hiroshima-u.ac.jp (T. Sakaguchi).

gag protein is released into the culture medium when expressed in the absence of other viral proteins, forming VLPs that resemble virus particles (Freed, 2002). In negative-strand RNA viruses, M protein-deficient viruses have been generated by using the virus recovery system from cDNA in rabies virus (Mebatsion et al., 1996), measles virus (Cathomen et al., 1998), and SeV (Inoue et al., 2003a). These viruses are invariably defective in virus budding. Furthermore, expression of the M protein or its analogs in the absence of other viral proteins leads to its release into the medium in a lipid-containing vesicle, as was observed for the M protein of vesicular stomatitis virus (VSV) (Justice et al., 1995; Li et al., 1993; Sakaguchi et al., 1999), M1 of influenza virus (Gomez-Puertas et al., 2000; Latham and Galarza, 2001), and VP40 of Ebola virus (Harty et al., 2000; Timmins et al., 2001). In VSV and Ebola virus, ca. 20–40% of the M protein synthesized in cells was released into the medium (Justice et al., 1995; Sakaguchi et al., 1999; Timmins et al., 2001). The M protein of parainfluenzavirus type 1 (PIV1), a paramyxovirus belonging to the same genus *Respirovirus* as SeV, is also released into the culture medium when expressed alone (Coronel et al., 1999). Co-expression of M and N proteins causes release of vesicles enclosing nucleocapsid-like structures (Coronel et al., 1999). It has also been shown that expression of the SeV M protein results in its release from cells (Sakaguchi et al., 1999; Takimoto et al., 2001). Moreover, the F protein as well as the M protein has been shown to form vesicles to be released when expressed alone, and protein motifs necessary for the release, including putative actin-binding motifs, have been identified (Takimoto et al., 2001). However, a quantitative study on the release has not been performed.

Schmitt et al. (2002) generated VLPs that resembled authentic virus particles by expressing proteins of simian virus 5 (SV5), a member of the genus *Rubulavirus* of the family *Paramyxoviridae*, and demonstrated that expression of the M protein alone was not sufficient for its release from cells but that simultaneous expression of the M protein, N protein, and one of the viral glycoproteins, F and HN proteins, was necessary for efficient VLP release from cells. The results of that study show that interactions among multiple viral proteins, not the M protein alone, confer budding competence on VLP, suggesting a different mechanism of paramyxovirus budding.

To further clarify the mechanism of paramyxovirus assembly and budding by using a VLP system, it is important to investigate the effects of other viral proteins, in addition to the M protein, on VLP formation. In the present study, we generated VLPs by co-expressing SeV proteins in various combinations, and we evaluated the contribution of each viral protein to budding by quantifying VLP release from cells. Furthermore, roles of each viral protein in VLP formation towards an authentic virus particle were also investigated by estimating density of the VLPs and by electron microscopy. The results showed that the M

protein was indeed a major driving force of SeV budding and that the F and HN proteins had enhancing and suppressive effects on budding, respectively. Furthermore, we show that the four viral proteins M, N, F, and HN, are required for formation of VLPs with density and morphology similar to those of authentic SeV particles and that the C protein enhances VLP release.

Results

VLP formation by expression of SeV M, N, F, and HN proteins

SeV M, N, F, and HN proteins were simultaneously expressed in 293T cells and metabolically labeled with [³⁵S]cysteine and [³⁵S]methionine. The culture medium was then collected and directly fractionated by sucrose floatation ultracentrifugation. Viral proteins in the floated fraction showed that these four proteins were released in the form of lipid-containing vesicles (Fig. 1A). Viral proteins in the cells were also analyzed, and the fraction of the released M protein was calculated as described in Materials and methods. The released fraction was 3.6%, which was ca. 1/5 of that of virus particles from infected cells (18.3%) (Fig. 1A).

Sucrose density equilibrium ultracentrifugation of the culture supernatant demonstrated that the M, N, F, and HN proteins were concentrated to fraction 14 (density = 1.17–1.20 g/ml), which was identical to that of authentic virus particles (Fig. 1B). Electron microscopy with negative staining showed the existence of virus-like particles (VLPs) that appeared to be similar to authentic virus particles (Fig. 1C). Herring bone-like, nucleocapsid-like structures were also found beside the VLPs (Fig. 1C). This finding is consistent with a previously reported finding that expression of the SeV N protein in cells resulted in generation of nucleocapsid-like structures (Buchholz et al., 1993). The VLPs seem to contain RNA actually because radioactivity was found at fractions 14–16 in [³H]uridine labeling (data not shown). These results indicate that simultaneous expression of the M, N, F, and HN proteins yielded VLPs with morphology and density similar to those of actual virus particles, suggesting that VLP formation can be a model for virus budding. The release efficiency of the VLPs was, however, significantly lower than that of SeV from infected cells.

Amounts of the N protein in the VLPs and virus particles were compared with those of other viral proteins after sucrose density equilibrium ultracentrifugation. Ratios of N protein to M protein in fraction 14 in Fig. 1B were 1.6 for the VLP and 0.7 for the SeV particle. The VLP was shown to contain more N proteins than the amount in the SeV particle. The ratios of other proteins in VLPs and SeV particles appeared to be similar.

We added an exogenous neuraminidase to the medium to prevent VLPs from being trapped on the cell surface by the




Fig. 1. Comparison of VLPs by co-expression of M, N, F, and HN proteins and SeV. (A) 293T cells were transfected with plasmids for expression of M, N, F, and HN proteins or infected with SeV at an m.o.i. of 10 and labeled with [³⁵S]cysteine and [³⁵S]methionine from 24 to 48 h post-transfection. The medium was then separated by sucrose floatation ultracentrifugation, and proteins in the floated fraction were analyzed by immunoprecipitation and SDS-PAGE. Proteins in the cells were also analyzed, and the released fraction of the M protein is shown in the figure. F₀: precursor of the F protein before proteolytic processing. Proteins from 1/15 of the cell lysates and those from half of the medium were run in a lane. (B) The medium from the labeled cells was then separated by sucrose density equilibrium ultracentrifugation in a 20–50% continuous gradient. Fractions were collected, and SeV proteins in each fraction were analyzed by immunoprecipitation and SDS-PAGE. Density of fractions was measured by weighing each fraction. (C) The medium from transfected 293T cells was concentrated by ultracentrifugation at 24000 rpm for 1 h through a 7% (w/w) sucrose cushion. The pellet was then suspended in PBS, processed for negative staining, and observed by electron microscopy. Arrowheads indicate nucleocapsid-like structures.

hemagglutinating activity. The addition improved VLP release by ca. 2-fold in some experiments, although it was not always reproducible. The medium was supplemented with neuraminidase in all of the experiments in this study.

Contribution of each SeV protein to VLP release from cells

We investigated the role of each SeV protein in VLP formation. Expression of the M protein alone led to an efficient release of M proteins into the medium (Fig. 2A). The efficiency of the M protein release was calculated to be 14.5%. The F protein was also released but with less efficiency (0.7%) (Fig. 2A). Only a trace amount of proteins

was released when either the N or HN protein was expressed (Fig. 2A).

Expression of the F protein with the M protein increased the released fractions of both proteins, especially that of the F protein significantly (from 0.7% to 6.5%) (Fig. 2B), suggesting a synergic effect of protein release. In contrast, expression of the HN protein with the M protein resulted in suppression of M protein release (from 14.5% to 0.6%), although the released fraction of the HN protein itself was slightly increased from 0.1% to 0.4%. Expression of the N protein with the M protein also decreased the released fraction of the M protein to 3.2%, while it increased the released fraction of the N protein from 0.03% to 0.4% (Fig.




Fig. 2. Protein release by expression of single or double SeV proteins. A single plasmid (A) or two plasmids (B) as indicated in the figure were introduced into 293T cells and labeled with [³⁵S]cysteine and [³⁵S]methionine from 24 to 48 h post-transfection. The vesicles released were concentrated by sucrose floatation ultracentrifugation, and proteins were analyzed by immunoprecipitation and SDS-PAGE. Proteins in the cells were also analyzed, and protein release was calculated by each protein (A) and by the M protein (B). Asterisk: protein release was calculated by the HN protein. Proteins from 1/15 of the cell lysates and those from half of the medium were run in a lane in these gels.

2B). HN and N proteins could be a burden for M-driven vesicle release. Co-expression of the two glycoproteins, F and HN, did not result in efficient release of these proteins (Fig. 2B).

An apparent constant intracellular level of the M protein in Fig. 2B does not seem to accord with the fact that the

released fraction of M protein varied from 0.6% to 17.9%; intracellular M protein level should vary in accordance with the variation in the released fraction. This is due to the sample amount loaded on the gel as described in Materials and methods (1/15 of the cell lysates and half of the medium). The difference between the amounts of M proteins in cells was therefore compressed to 1/7.5, making it difficult to detect the difference between levels of intracellular M protein.

Expression of the M, N, F, and HN proteins resulted in formation of a VLP as described above. Removal of the M protein from this combination resulted in complete suppression of VLP release, supporting the notion that the M protein is a major driving force for release (Fig. 3A). Removal of the F protein also reduced the released proteins to 0.5%, indicating that the F protein has a release-promoting effect (Fig. 3A). Removal of the N protein did not significantly affect the efficiency of release in this case (Fig. 3A). It is notable that without the HN protein, release of the remaining proteins, M, F, and N proteins, was enhanced (8.3%; Fig. 3A). An increase in amounts of transfected HN plasmids resulted in greater suppression of VLP release (Fig. 3B), confirming that the HN protein has an inhibitory effect on release. The inhibitory effect may not be due to cell toxicity of the HN protein because viral protein synthesis appeared to be constant in the transfected cells (Fig. 3B) and no apparent CPE was observed (data not shown). For experiments in this study, 0.5 μg of the HN plasmid was used to adjust the intracellular expression level of HN protein to that in SeV-infected cells.

Acceleration of VLP release by co-expression of the C protein

Effects of nonstructural proteins, C and V proteins, on the VLP release were further examined. Expression of the C protein together with M, N, F, and HN proteins enhanced VLP release by more than 2-fold (Fig. 4). The enhancement was highly reproducible (Fig. 4), showing that the C protein increased the efficiency of VLP release. In contrast, the V protein did not have such an enhancing activity (data not shown). The fraction of M released into VLPs formed by M, N, F, HN, and C was 9.8%, almost half of the M fraction released into SeV particles (Fig. 4).

Density and morphology of structures released by expression of viral proteins in various combinations

We performed sucrose density equilibrium ultracentrifugation to determine the density of released proteins. M protein released by single expression showed a wide range of densities, indicating heterogeneity of M protein-containing structures (Fig. 5). The M protein was found in abundance in fractions 8 to 16 (1.09–1.22 g/ml). The M protein was considered to be released in association with




Fig. 3. (A) Contribution of SeV proteins to VLP release from cells. 293T cells were transfected with multiple plasmids as indicated in the figure and labeled with [³⁵S]cysteine and [³⁵S]methionine from 24 to 48 h post-transfection. The medium was then separated by sucrose floatation ultracentrifugation, and proteins in the floated fraction were analyzed by immunoprecipitation and SDS-PAGE. Proteins in the cells were also analyzed, and protein release was calculated by the M protein. (B) Effect of the HN protein on VLP release. The M, N, and F plasmids together with increasing amounts of the HN plasmid were introduced into 293T cells, and proteins were analyzed. Proteins from 1/15 of the cell lysates and those from half of the medium were run in a lane in these gels.

lipids because treatment with 1% Triton X-100 before ultracentrifugation shifted the distribution (data not shown). The singly expressed F protein was distributed in a narrow

range around fraction 14 (1.17–1.20 g/ml) (Fig. 5), and released N protein was slightly detected in a heavier fraction, fraction 16 (1.20–1.22 g/ml) (Fig. 5).




Fig. 4. Effect of C protein on VLP release from cells. 293T cells were transfected with multiple plasmids with or without the C plasmid as indicated in the figure and labeled with [³⁵S]cysteine and [³⁵S]methionine from 24 to 48 h post-transfection. The medium was then separated by sucrose floatation ultracentrifugation, and proteins in the floated fraction were analyzed by immunoprecipitation and SDS-PAGE. Proteins in the cells were also analyzed similarly, and protein release was calculated by the M protein. Proteins from 1/15 of the cell lysates and those from half of the medium were run in a lane. The graph indicates the ratio of fractions of M released into VLPs from four independent experiments. Error bar indicates standard deviation.

When the F protein was expressed with the M protein, these two proteins co-existed mainly in fractions 12 and 14 (Fig. 5, M + F). The distribution of the M protein was shifted into these fractions (Fig. 5, M + F). A band between the M and F₀ proteins was considered to be β -actin because it reacted with anti- β -actin antibody in immunoblotting (data not shown) as described previously (Takimoto et al., 2001). Expression of the N protein with the M protein resulted in co-existence of N and M proteins in a fraction similar to that when the N protein was singly expressed (Fig. 5, M + N). On the other hand, a significant amount of the M protein was found in fractions 8–12 (Fig. 5, M + N), probably having been released independently of the release of the N protein. The changes in distribution and amounts of released proteins by co-expression suggest interactions between F and M proteins and between M and N proteins. In contrast, simultaneous expression of F and N proteins caused no change in protein release or in density distribution compared with those in the case of single expressions (data not shown).

Triple expression of M, N, and F proteins caused co-localization of these three proteins in fraction 14, suggesting that a significant amount of these proteins interacted and formed VLPs with density similar to that of authentic virus

particles (Fig. 5, M + N + F). On the other hand, some N proteins were found in a heavier fraction, fraction 18, and some F₀ proteins were found in the lighter fractions, fractions 10 and 12, suggesting that some proteins were independently released probably in heterogeneous VLPs. Triple expression of M, N, and HN proteins caused less VLP release in total, but the proteins were fairly concentrated to fraction 14 (Fig. 5, M + N + HN). The glycoproteins F and HN appeared to guide M and N proteins to fraction 14.

Simultaneous expression of M, N, F, and HN proteins resulted in concentration almost all of these proteins to fraction 14, suggesting formation of homogenous VLPs with density similar to that of virus particles (Fig. 1B). Additional expression of the C protein with the four proteins did not alter the distribution of the proteins, although amounts of the proteins were increased overall (data not shown). Convergence by co-expression of viral proteins to fraction 14, which had the same density as SeV particles, was apparent when the percent distribution of the M protein was plotted in a graph (Fig. 5).

Negative staining and electron microscopy demonstrated that the supernatant from the cells expressing only the M




Fig. 5. Distributions of densities of VLPs with an increasing number of plasmids. Plasmids for expression of a single viral protein (M, F, or N) or those for expression of multiple viral proteins (M + F, M + N, M + N + F, or M + N + HN) were introduced into 293T cells and labeled with [³⁵S]cysteine and [³⁵S]methionine from 24 to 48 h post-transfection. The medium was then separated by sucrose density equilibrium ultracentrifugation in a 20–50% continuous gradient. Fractions were taken and SeV proteins in each fraction were analyzed by immunoprecipitation and SDS-PAGE. (Graph) Percent distributions of the M protein in the results from each combination of plasmids in Fig. 1B (M + N + F + HN, SeV) and this figure (M, M + F, M + N) are plotted in a graph.

protein had vesicles with smooth surfaces (Fig. 6A). The vesicles from the cells expressing M and F proteins had rough surfaces with some geometric patterns, indicating the




Fig. 6. Electron microscopy of structures released from transfected cells. The medium from transfected 293T cells was clarified by low-speed centrifugation, passed through a 5- μ m filter, and centrifuged at 24000 rpm for 1 h through a 7% (w/w) sucrose cushion. The pellet was resuspended in PBS, processed for negative staining, and observed by electron microscopy. (A) Single expression of M. (B) Double expression of M and F. (Inlet) Magnification of the surface of the VLP. (C) Triple expression of M, N, and F. Arrowheads indicate nucleocapsid-like structures. (Inlet) Magnification of the nucleocapsid-like structures.

presence of abundant spikes on the surfaces (Fig. 6B). Furthermore, the vesicles formed by M, F, and N proteins had nucleocapsid-like structures inside (Fig. 6C). There were also some structures outside the particles (Fig. 6C). Co-expression of M, N, F, and HN proteins generated VLPs similar to virus particles (Fig. 1C), although small vesicles were also seen in the VLPs (data not shown). There was no difference between the morphology of VLPs generated by co-expression of M, N, F, and HN proteins with the C protein and that without the C protein (data not shown).

Discussion

In the present study, we expressed SeV proteins and produced VLPs. Co-expression of M, N, F, and HN proteins and sucrose density equilibrium ultracentrifugation concentrated these proteins into a common fraction, to which the authentic virus particles migrated, indicating that these proteins autonomously assembled into VLPs that are comparable to the authentic virus particles in terms of density. The similar densities seem to reflect the common compositions of the virus particles and the VLPs. The VLP formation can thus be used as a model for virus assembly and budding. In this condition, however, protein release was only one-fifth of that of SeV. A higher level of release, almost half of the efficiency of SeV, was obtained by co-expression of C protein together with M, N, F, and HN proteins. To get closer the efficiency of VLP release to that of virus release, some other viral proteins or the nucleocapsid containing the full-length genomic RNA might be necessary.

Schmitt et al. (2002) expressed multiple proteins of SV5, a paramyxovirus classified to the genus distinct from that of SeV, in 293T cells to generate VLPs (Schmitt et al., 2002). The study shows that the M protein alone does not result in generation of VLPs from cells, but co-expression of the N protein and one of the glycoproteins, F or HN protein, together with the M protein is necessary for efficient VLP budding. This situation is different from that of SeV. Furthermore, the glycoproteins, F and HN proteins, have similar budding-promoting effects in SV5, whereas in SeV, the F protein was promoting and the HN protein was inhibitory for VLP budding. The differences revealed by VLP formation may indicate differences of mechanism of virus budding between SV5 and SeV.

An intracellular nucleocapsid structure formed by single expression of the N protein has been reported in paramyxoviruses: SeV (Buchholz et al., 1993), measles virus (Spehner et al., 1991), and Newcastle disease virus (Errington and Emmerson, 1997). Once formed in cells, the nucleocapsid-like structure could be a substitute for the nucleocapsid in VLP budding. We found that the ratio of the N protein to other viral proteins in VLPs was different to that in the virus particles; the ratios of the N protein to the M protein were 1.6:1 in VLPs and 0.7:1 in the virus particles.

The N protein in VLPs appeared to be more abundant than that in the virus, as had been observed in VLP formation in SV5 (Schmitt et al., 2002). The VLPs may contain nucleocapsid-like structures of various lengths, almost all of which are probably shorter than the viral nucleocapsid (15384 bases). Such differences in length may affect the N protein ratio because difference in length affects the nucleocapsid incorporation and budding as shown by using defective interfering particles (Mottet and Roux, 1989).

Interaction between the M protein and viral glycoproteins has been shown by using biochemical and cell biological methods (Yoshida et al., 1976, 1979, 1986) and by the use of live viruses whose cytoplasmic tails of the glycoproteins were deleted (Fouillot-Coriou and Roux, 2000). Recently, Ali and Nayak (2000) showed the interaction of M and glycoproteins in a raft domain by solubilizing cells with a nonionic detergent and a subsequent sucrose floatation. The shift of fractions observed in the sucrose density ultracentrifugation of VLPs suggested the interaction. On the other hand, Takimoto et al. (2001) did not suggest the interaction, based on the observation that the co-expressed and released M and F proteins were in distinct fractions after sucrose density equilibrium ultracentrifugation, although they suggested a functional interaction by release acceleration of both of the proteins. The reason for the contradiction with ours is unknown. The present study also suggested protein–protein interaction between M and N. This is consistent with the previous reports (Coronel et al., 1999, 2001; Yoshida et al., 1976).

Fouillot-Coriou and Roux (2000) showed by using recombinant SeVs possessing cytoplasmic tail-deleted glycoproteins that a partial deletion of the F tail caused the virus to bud inefficiently, while the rates of incorporation of the F protein to other viral proteins were almost constant. It seems that the F protein is essential for virus budding, as if it is a part of the budding machinery. On the other hand, the tail-less HN basically had no effect on virus budding, and HN mutants are not incorporated in some cases in a cytoplasmic motif-dependent fashion (Fouillot-Coriou and Roux, 2000; Takimoto et al., 1998). Furthermore, efficient budding of an HN-deficient SeV has been reported (Inoue et al., 2003b; Leyrer et al., 1998; Stricker and Roux, 1991). These results suggest that SeV F and HN proteins have different roles in virus budding. Our study showed that the F protein had a promoting effect on VLP budding, while the HN protein had an inhibitory effect. Although Takimoto et al. (2001) demonstrated that the HN protein did not have such an inhibitory effect on M-driven vesicle release, the reason of the discrepancy is not known. The HN protein increased VLPs of uniform density (Fig. 5) and may have enhanced the integrity of VLPs.

Hasan et al. (2000) reported that SeV lacking all of the four C proteins yielded less virus particles and that the particles were irregular in shape, suggesting a role of the C protein in virus assembly and budding. In the present study, addition of the C protein to the VLP system enhanced VLP

release from cells. This is strong evidence that a paramyxovirus accessory protein affects virus budding. In infected cells, the exogenous C protein has a suppressive effect on RNA synthesis (Curran et al., 1992; Horikami et al., 1997). Thus, the function of the C protein in virus budding had been difficult to analyze in virus-infected cells. The present VLP system could illustrate the action of the C protein on virus budding. However, the mechanism of acceleration of VLP release by the C protein is unknown and to be resolved. The C protein is known to co-localize with the M and HN proteins in infected cells (Hasan et al., 2000), and it is thought that the C protein acts as a molecular chaperon to facilitate assembly of viral proteins by interacting with M protein. Although the C protein has been shown to interact with the L protein (Horikami et al., 1997), the interaction may not be involved in VLP release because the VLP-forming system in the present study lacked the L protein.

The acceleration of VLP release by the C protein is limited to only 2- to 3-fold, while a C-knockout virus suppressed virus formation by ca. 100-fold (Hasan et al., 2000). Because the C protein has various functions, including anti-interferon activity (Garcin et al., 1999; Gotoh et al., 1999) and inhibition of viral RNA synthesis (Curran et al., 1992; Horikami et al., 1997), the extremely low yield of C-knockout virus may be due to the summation of impediments of these functions in addition to that of the budding-enhancing activity identified in this work.

In summary, we have established a VLP production system of SeV. The generated VLPs had density similar to that of actual virus particles, and the released VLPs were comparable to the virus particles. A novel finding by using the VLP system was that the C protein directly facilitated virus budding. The current VLP system will be useful in further research on virus budding, including research to develop antiviral drugs targeting virus assembly and vaccine development by using VLPs as an immunogen.

Materials and methods

Cells and a virus

293T cells, human renal epithelial cells expressing the SV40 large T antigen, were propagated in Dulbecco's modified Eagle's minimal essential medium (DMEM) supplemented with glutamine and 10% fetal calf serum. Recombinant SeV derived from the Z strain (Kato et al., 1996) was propagated in embryonated chicken eggs as described previously (Kiyotani et al., 1990).

Plasmids

The plasmids, pCAGGS-M, pCAGGS-N, pCAGGS-F and pCAGGS-HN, for mammalian expression of SeV proteins under the chicken β -actin promoter (Niwa et al., 1991) were described previously (Sakaguchi et al., 1999).

The expression plasmid for the C protein, pCAGGS-C, was constructed in this study.

Transfection, infection, and metabolic labeling

Subconfluent 293T cells were transfected with plasmids by using the FuGENE6 transfection reagent (Roche Diagnostics, Indianapolis, IN). For a 60-mm dish, 3.5 µg of plasmids were used in cotransfection experiments: pCAGGS-M, 1 µg; pCAGGS-F, 1 µg; pCAGGS-N, 0.5 µg; pCAGGS-HN, 0.5 µg; pCAGGS-C, 0.5 µg. The plasmid amounts were determined so that intracellular levels of protein expression were similar to those in virus-infected cells. In the case of omission of an expression plasmid, a vector plasmid, pCAGGS, was added to keep the total amount of transfected DNA constant. For a 100-mm dish, a 3-fold larger amount of the plasmids was used. Alternatively, 293T cells were infected with SeV at an m.o.i. of 10.

For metabolic labeling of viral proteins, the medium of transfected or infected 293T cells was replaced with 1.5 ml of DMEM containing one-tenth of the normal amounts of cysteine and methionine and 2.5 MBq/ml of [³⁵S]cysteine and [³⁵S]methionine mixture ([³⁵S]Pro-mix, Amersham Biosciences, Piscataway, NJ), together with 10 mU of bacterial neuraminidase (Roche Diagnostics) after 24 h. After 48 h, the medium and cells were collected separately.

Sucrose floatation and sucrose density equilibrium ultracentrifugation

For a sucrose floatation assay, the medium was clarified by centrifugation at 7000 rpm for 5 min, and 1.4 ml of the supernatant was mixed with 2.1 g sucrose to adjust its concentration to 60% (w/w). The supernatant was then transferred to a centrifuge tube, overlaid with 7 ml of 50% (w/w) sucrose/phosphate-buffered saline (PBS) and 0.5 ml of 10% (w/w) sucrose/PBS, and centrifuged at 35000 rpm for 18 h in a RPS40T rotor (Hitachi, Tokyo, Japan). The top 1.5-ml fraction including the 10% and 50% sucrose boundary was collected and solubilized in a radioimmunoprecipitation assay (RIPA) buffer [10 mM Tris-HCl, pH 7.4, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), and 150 mM NaCl] containing 50 mM iodoacetamide (IAA) and 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were solubilized in a RIPA buffer containing IAA and PMSF and then centrifuged at 15000 rpm for 20 min to remove nuclei and cell debris.

For sucrose density equilibrium ultracentrifugation, the medium was clarified at 7000 rpm for 5 min and was layered onto the top of a 20–50% sucrose/PBS linear density gradient and centrifuged at 35000 rpm for 18 h in a RPS40T rotor. Fractions were obtained by using an Auto Densi-Flow fractionator (Labconco, Kansas City, MO). Density of fractions was measured by weighing each fraction. Proteins in the fractions were solubilized by adding concentrated RIPA buffer containing IAA and PMSF.

Immunoprecipitation and SDS-PAGE

Solubilized proteins in the RIPA buffer were mixed with 2 µl of anti-SeV serum, 1 µl of anti-C serum (kindly provided by A. Kato), and 30 µl of Protein A Sepharose beads, followed by agitation for 18 h at 4 °C. Immune complexes were washed three times with the RIPA buffer, suspended in SDS sample buffer, and boiled for 3 min as described previously (Sakaguchi et al., 1996). Proteins were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) using an 11% gel, and protein bands were visualized and quantitated by using a BAS2000 image analyzer (Fuji Film, Tokyo, Japan). The fraction of viral proteins released into the medium was calculated basically as the ratio of the M protein detected in the medium to the total M protein both in the medium and the cells. Proteins from 1/15 of the cell lysates and those from half of the medium were run in a lane in these gels.

Electron microscopy

For electron microscopy, subconfluent 293T cells in 100-mm dishes were transfected with plasmids, and after 48 h, the media were clarified by low-speed centrifugation and passed through a Millex-SV filter with a pore size of 5.0 µm (Millipore, Bedford, MA) to completely remove cells and then pelleted through a 7% (w/w) sucrose/PBS cushion by ultracentrifugation at 24000 rpm for 1 h. The pellet was resuspended in PBS, placed on Formvar-carbon-coated nickel grids, stained with 4% uranyl acetate, and examined under a JEOL JEM-1200EX II transmission electron microscope as described previously (Uchiyama and Uchida, 1988).

Acknowledgments

We thank Yoshiyuki Nagai, Atsushi Kato, and Makoto Inoue for supplying an antibody and for their helpful discussions, and we thank the staff of the Research Center for Molecular Medicine, Hiroshima University School of Medicine, for allowing us the use of their facilities. This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science.

References

- Accola, M.A., Strack, B., Gottlinger, H.G., 2000. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. *J. Virol.* 74, 5395–5402.
- Ali, A., Nayak, D.P., 2000. Assembly of Sendai virus: M protein interacts with F and HN proteins and with the cytoplasmic tail and transmembrane domain of F protein. *Virology* 276, 289–303.
- Buchholz, C.J., Spehner, D., Drillien, R., Neubert, W.J., Homann, H.E., 1993. The conserved N-terminal region of Sendai virus nucleocapsid

- protein NP is required for nucleocapsid assembly. *J. Virol.* 67, 5803–5812.
- Cathomen, T., Mrkic, B., Spehner, D., Drillien, R., Naef, R., Pavlovic, J., Aguzzi, A., Billeter, M.A., Cattaneo, R., 1998. A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. *EMBO J.* 17, 3899–3908.
- Coronel, E.C., Murti, K.G., Takimoto, T., Portner, A., 1999. Human parainfluenza virus type 1 matrix and nucleoprotein genes transiently expressed in mammalian cells induce the release of virus-like particles containing nucleocapsid-like structures. *J. Virol.* 73, 7035–7038.
- Coronel, E.C., Takimoto, T., Murti, K.G., Varich, N., Portner, A., 2001. Nucleocapsid incorporation into parainfluenza virus is regulated by specific interaction with matrix protein. *J. Virol.* 75, 1117–1123.
- Curran, J., Marq, J.B., Kolakofsky, D., 1992. The Sendai virus nonstructural C proteins specifically inhibit viral mRNA synthesis. *Virology* 189, 647–656.
- Errington, W., Emmerson, P.T., 1997. Assembly of recombinant Newcastle disease virus nucleocapsid protein into nucleocapsid-like structures is inhibited by the phosphoprotein. *J. Gen. Virol.* 78, 2335–2339.
- Fouillot-Coriou, N., Roux, L., 2000. Structure–function analysis of the Sendai virus F and HN cytoplasmic domain: different role for the two proteins in the production of virus particle. *Virology* 270, 464–475.
- Freed, E.O., 2002. Viral late domains. *J. Virol.* 76, 4679–4687.
- Garcin, D., Latorre, P., Kolakofsky, D., 1999. Sendai virus C proteins counteract the interferon-mediated induction of an antiviral state. *J. Virol.* 73, 6559–6565.
- Gomez-Puertas, P., Albo, C., Perez-Pastrana, E., Vivo, A., Portela, A., 2000. Influenza virus matrix protein is the major driving force in virus budding. *J. Virol.* 74, 11538–11547.
- Gotoh, B., Takeuchi, K., Komatsu, T., Yokoo, J., Kimura, Y., Kurotani, A., Kato, A., Nagai, Y., 1999. Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon- α / β -mediated responses. *FEBS Lett.* 459, 205–210.
- Harty, R.N., Brown, M.E., Wang, G., Huibregtse, J., Hayes, F.P., 2000. A PPXY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. *Proc. Natl. Acad. Sci. U.S.A.* 97, 13871–13876.
- Hasan, M.K., Kato, A., Muranaka, M., Yamaguchi, R., Sakai, Y., Hatano, I., Tashiro, M., Nagai, Y., 2000. Versatility of the accessory C proteins of Sendai virus: contribution to virus assembly as an additional role. *J. Virol.* 74, 5619–5628.
- Horikami, S.M., Hector, R.E., Smallwood, S., Moyer, S.A., 1997. The Sendai virus C protein binds the L polymerase protein to inhibit viral RNA synthesis. *Virology* 235, 261–270.
- Inoue, M., Tokusumi, Y., Ban, H., Kanaya, T., Shirakura, M., Tokusumi, T., Hirata, T., Nagai, Y., Iida, A., Hasegawa, M., 2003a. A new Sendai virus vector deficient in the matrix gene does not form virus particles and shows extensive cell-to-cell spreading. *J. Virol.* 77, 6419–6429.
- Inoue, M., Tokusumi, Y., Ban, H., Kanaya, T., Tokusumi, T., Nagai, Y., Iida, A., Hasegawa, M., 2003b. Nontransmissible virus-like particle formation by F-deficient Sendai virus is temperature sensitive and reduced by mutations in M and HN proteins. *J. Virol.* 77, 3238–3246.
- Justice, P.A., Sun, W., Li, Y., Ye, Z., Grigera, P.R., Wagner, R.R., 1995. Membrane vesiculation function and exocytosis of wild-type and mutant matrix proteins of vesicular stomatitis virus. *J. Virol.* 69, 3156–3160.
- Kato, A., Sakai, Y., Shiota, T., Kondo, T., Nakanishi, M., Nagai, Y., 1996. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. *Genes Cells* 1, 569–579.
- Kiyotani, K., Takao, S., Sakaguchi, T., Yoshida, T., 1990. Immediate protection of mice from lethal wild-type Sendai virus (HVJ) infections by a temperature-sensitive mutant, HVJpi, possessing homologous interfering capacity. *Virology* 177, 65–74.
- Lamb, R.A., Kolakofsky, D., 2001. Paramyxoviridae: the viruses and their replication. In: Knipe, D.M., Howley, P.M. (Eds.), *Fields Virology*, vol. 1, 4th ed. Lippincott Williams & Wilkins, Philadelphia, pp. 1305–1340.
- Latham, T., Galarza, J.M., 2001. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. *J. Virol.* 75, 6154–6165.
- Leyrer, S., Bitzer, M., Lauer, U., Kramer, J., Neubert, W.J., Sedlmeier, R., 1998. Sendai virus-like particles devoid of haemagglutinin-neuraminidase protein infect cells via the human asialoglycoprotein receptor. *J. Gen. Virol.* 79, 683–687.
- Li, Y., Luo, L., Schubert, M., Wagner, R.R., Kang, C.Y., 1993. Viral liposomes released from insect cells infected with recombinant baculovirus expressing the matrix protein of vesicular stomatitis virus. *J. Virol.* 67, 4415–4420.
- Mebastion, T., Koenig, M., Conzelmann, K.K., 1996. Budding of rabies virus particles in the absence of the spike glycoprotein. *Cell* 84, 941–951.
- Mottet, G., Roux, L., 1989. Budding efficiency of Sendai virus nucleocapsids: influence of size and ends of the RNA. *Virus Res.* 14, 175–187.
- Nagai, Y., 1999. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. *Rev. Med. Virol.* 9, 83–99.
- Niwa, H., Yamamura, K., Miyazaki, J., 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* 108, 193–199.
- Peebles, M.E., 1991. Paramyxovirus M proteins: pulling it all together and taking it on the road. In: Kingsbury, D.W. (Ed.), *The Paramyxoviruses*. Plenum, New York, pp. 427–456.
- Sakaguchi, T., Leser, G.P., Lamb, R.A., 1996. The ion channel activity of the influenza virus M₂ protein affects transport through the Golgi apparatus. *J. Cell Biol.* 133, 733–747.
- Sakaguchi, T., Uchiyama, T., Fujii, Y., Kiyotani, K., Kato, A., Nagai, Y., Kawai, A., Yoshida, T., 1999. Double-layered membrane vesicles released from mammalian cells infected with Sendai virus expressing the matrix protein of vesicular stomatitis virus. *Virology* 263, 230–243.
- Schmitt, A.P., Leser, G.P., Waning, D.L., Lamb, R.A., 2002. Requirements for budding of paramyxovirus simian virus 5 virus-like particles. *J. Virol.* 76, 3952–3964.
- Spehner, D., Kim, A., Drillien, R., 1991. Assembly of nucleocapsid-like structures in animal cells infected with a vaccinia virus recombinant encoding the measles virus nucleoprotein. *J. Virol.* 65, 6296–6300.
- Stricker, R., Roux, L., 1991. The major glycoprotein of Sendai virus is dispensable for efficient virus particle budding. *J. Gen. Virol.* 72, 1703–1707.
- Takimoto, T., Bousse, T., Coronel, E.C., Scroggs, R.A., Portner, A., 1998. Cytoplasmic domain of Sendai virus HN protein contains a specific sequence required for its incorporation into virions. *J. Virol.* 72, 9747–9754.
- Takimoto, T., Murti, K.G., Bousse, T., Scroggs, R.A., Portner, A., 2001. Role of matrix and fusion proteins in budding of Sendai virus. *J. Virol.* 75, 11384–11391.
- Timmins, J., Scianimanico, S., Schoehn, G., Weissenhorn, W., 2001. Vesicular release of Ebola virus matrix protein VP40. *Virology* 283, 1–6.
- Uchiyama, T., Uchida, T., 1988. Ultrastructural study on Japanese isolates of spotted fever group rickettsiae. *Microbiol. Immunol.* 32, 1163–1166.
- Yoshida, T., Nagai, Y., Yoshii, S., Maeno, K., Matsumoto, T., Hoshino, M., 1976. Membrane (M) protein of HVJ (Sendai virus): its role in virus assembly. *Virology* 71, 143–161.
- Yoshida, T., Nagai, Y., Maeno, K., Iinuma, M., Hamaguchi, M., Matsumoto, T., Nagayoshi, S., Hoshino, M., 1979. Studies on the role of M protein in virus assembly using a ts mutant of HVJ (Sendai virus). *Virology* 92, 139–154.
- Yoshida, T., Nakayama, Y., Nagura, H., Toyoda, T., Nishikawa, K., Hamaguchi, M., Nagai, Y., 1986. Inhibition of the assembly of Newcastle disease virus by monensin. *Virus Res.* 4, 179–195.

Original article

Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation

Mikako Fujita ^{a,*}, Hirofumi Akari ^b, Akiko Sakurai ^a, Akiko Yoshida ^a, Tomoki Chiba ^c,
Keiji Tanaka ^c, Klaus Strebel ^d, Akio Adachi ^a

^a Department of Virology, The University of Tokushima, Graduate School of Medicine, 3-18-15 Kuaramoto-cho, Tokushima-shi Tokushima 770-8503, Japan

^b Tsukuba Primate Center for Medical Sciences, National Institute of Infectious Diseases, Tsukuba, Ibaraki 305-0843, Japan

^c Tokyo Metropolitan Institute of Medical Science, Bunkyo-ku, Tokyo 113-8613, Japan

^d Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892-0460, USA

Received 29 March 2004; accepted 13 April 2004

Available online 07 June 2004

Abstract

While the Vif protein of human immunodeficiency virus type 1 (HIV-1) is essential for viral replication in non-permissive cells, it is rapidly degraded intracellularly. We have previously suggested that the rapid turn-over of Vif is biologically meaningful to prevent detrimental effects of this protein at high expression levels. We now studied the mechanism of Vif degradation by examining the blocking effect of protease inhibitors in pulse/chase experiments and by monitoring the extent of Vif ubiquitination. The rapid turn-over of Vif could be blocked by proteasome inhibitors, and Vif was highly ubiquitinated. Cytoskeletal Vif was found to be more stable than soluble cytosolic Vif. These degradation characteristics of Vif were cell type-independent and observed in both non-permissive and permissive cells. Characterization of a series of *vif* deletion mutants showed that amino acids predicted to be important for formation of β -strand structures (amino acid nos. 63–70 and 86–89) were critical for maintaining a normal expression level of Vif and for viral infectivity. Finally, we performed comparative stability analysis of the four HIV-1 accessory proteins. Vif was unique in its short half-life and in the magnitude of the degradation. Taken together, we conclude that the proteasome degradation of HIV-1 Vif is a virologically important process and crucial for the function of Vif. © 2004 Elsevier SAS. All rights reserved.

Keywords: HIV-1; Vif; Proteasome degradation; Accessory proteins

1. Introduction

The Vif protein of HIV-1 is encoded by an accessory gene that is conserved in all known lentiviruses, except for equine infectious anemia virus [1], and is indispensable for viral replication in a certain type of cell (for review, see Refs. [2–5]). It acts during the stage of assembly, budding, or maturation to greatly augment the infectivity of progeny virions in a producer cell-dependent manner. Producer cells are, therefore, divided into permissive and non-permissive, and HIV-1 grown in non-permissive cells like primary human T cells and a restricted number of cell lines such as H9 and CEM is unable to replicate in any type of target cells in the

absence of Vif. Many cell lines, such as 293T and HeLa, are classified as permissive cells. Previous studies suggested that Vif counteracts certain cellular anti-HIV-1 factor(s) present in non-permissive cells [6,7]. Indeed, the recent identification of APOBEC3G (CEM15) as a cellular inhibitor of HIV-1 replication [8] confirmed this speculation on the existence of an inhibitory factor in non-permissive cell types. APOBEC3G was subsequently found to deaminate dC to dU in the newly synthesized minus strand DNA of HIV-1, resulting in G to A hypermutation of the viral plus strand DNA [9–12]. However, the mechanism by which Vif overcomes the function of APOBEC3G remains unclear. Some reports show that Vif induces proteasome-dependent degradation of APOBEC3G [13–16] while others report an effect on APOBEC3G translation [17,18] or both [19]. The precise degradation profile of Vif itself remains to be determined.

* Corresponding author. Tel.: +81-88-633-9232; fax: +81-88-633-7080.
E-mail address: mfujita@basic.med.tokushima-u.ac.jp (M. Fujita).

We have previously shown that Vif is rapidly decayed both in the absence and presence of APOBEC3G in transiently transfected HeLa cells, and that expression of Vif to an excessive level is inhibitory to viral replication [20]. In the current study we report that newly synthesized Vif is rapidly and similarly degraded in transiently transfected 293T, HeLa and H9 cells. We found that Vif present in detergent-resistant compartments was more stable than soluble cytosolic Vif. Treatment of 293T cells with proteasome inhibitors but not with inhibitors of lysosome degradation and the calpain system blocked the degradation of Vif. In fact, Vif was highly polyubiquitinated in the cells. We investigated the structural basis of stable expression of Vif by deletion analysis and found that amino acids in the predicted β -strand structures (amino acid nos. 63–70 and 86–89 in Vif) are critically important for a normal expression level of Vif and for viral infectivity. We further examined and compared the stability of all four HIV-1 accessory proteins. Rapid turn-over was demonstrated to be unique to Vif among the viral proteins tested. These results show that expression of Vif is controlled to be limited and optimal by proteasome degradation, and suggest that HIV-1 has apparently evolved to regulate Vif levels to suit its requirements for efficient replication and spread.

2. Materials and methods

2.1. Plasmids

The full-length molecular clone pNL432 was used for production of wild-type (wt) infectious virus [21]. Construction and characterization of proviral deletion mutants designated pNL-fE88del, -fW89del, -fR90del, -fK91del, -fK92del, and -fR93del have been previously described [22]. New proviral deletion mutants designated pNL-fL64del, -fV65del, -fI66del, and -fT67del, -fS86del, and -fI87del were constructed from pNL432 by the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) as previously described [22,23]. For efficient expression of wt Vif, the subgenomic expression vector pNL-A1 [24] was used. A pNL-A1 version of mutant Vif (E88del) expression vector designated pNLA1-E88del was constructed by insertion of the *NdeI*-*EcoRI* fragment of pNL-fE88del into the *NdeI* and *EcoRI* sites of pNL-A1. An HIV-1 Gag-p24 expression vector pSG-Gag (p24) cFLAG was constructed from pcDNA3 (Invitrogen Corp., Carlsbad, CA, USA) carrying FLAG (pcDNA3cFLAG) and pSG5 (Stratagene, La Jolla, CA, USA). The ubiquitin expression vector pcDNA3.1-HA-Ub constructed from pcDNA3.1 (Invitrogen, Corp., Carlsbad, CA, USA) [25] was used to monitor the ubiquitination of Vif.

2.2. Cells

H9 [26] cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum

(FBS). The 293T [27] and HeLa (ATCC CCL-2) cells were cultured in Dulbecco's modified Eagle medium supplemented with 10% heat-inactivated FBS.

2.3. Transfection

For transfection of H9 cells, the electroporation method was used, as previously described [21]. For transfection of HeLa and 293T cells, the calcium-phosphate coprecipitation method [21] or the LipofectAMINE PLUS™ system (Invitrogen Corp., Carlsbad, CA, USA) was used.

2.4. Pulse/chase analysis of viral proteins

Transfected cells were metabolically labeled for 5 min with the Redivue Pro-mix L-[³⁵S] in vitro cell labeling mix system (Amersham Biosciences Corp., Piscataway, NJ, USA). After the labeling, cells were pelleted and suspended in complete RPMI containing all amino acids and 10% FBS. Cells were incubated for various times at 37 °C as indicated in the text. Cells were then pelleted and stored at –80 °C. Cell pellets were subsequently extracted with CHAPS buffer (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 100 mM NaCl, and 0.5% (v/v) CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate)) supplemented with 0.2% deoxycholate (DOC), incubated on ice for 5 min, vortexed, and pelleted for 3 min at 15000 × g. Proteins in the supernatant were designated sol (soluble fraction). Proteins present in the pellet were solubilized by dissolving in PBS-Laemmli's sample buffer (1:1) and heating at 95 °C for 30 min. The solution was then centrifuged for 3 min at 15000 × g. Proteins in the resultant supernatant were designated insol (insoluble fraction). These two fractions were used for immunoprecipitation with a specific antibody. Immunoprecipitated proteins were solubilized by boiling in the sample buffer and separated by SDS-PAGE. Radioactive bands were visualized by fluorography and quantitated by scanning.

2.5. Western immunoblot analysis of viral proteins

Transfected 293T cells were collected and solubilized by the CHAPS/DOC method as above or by dissolving directly into Laemmli's sample buffer. For some experiments, cells collected were suspended in PBS, subjected to two cycles of freeze-thaw, and pelleted for 3 min at 15000 × g. Proteins in the supernatant were designated sol-1. Proteins in the pellet were solubilized by the CHAPS/DOC and pelleted for 3 min at 15000 × g. The resultant supernatant was designated sol-2. Proteins present in the pellet were solubilized by dissolving in PBS-Laemmli's sample buffer (1:1) and heating at 95 °C for 30 min. The solution was then centrifuged for 3 min at 15000 × g. Proteins in the resultant supernatant were designated insol. Protein samples were resolved by SDS-PAGE followed by electrophoretic transfer to polyvinylidene fluoride membranes. The membranes were treated with specific antibodies and visualized with the ECL plus Western Blot-

ting Detection System (Amersham Biosciences UK Limited, Buckinghamshire, England), as previously described [22,23].

2.6. Immunoprecipitation/western blot analysis of Vif ubiquitination

The 293T cells were transfected with pNL-A1, pcDNA3.1-HA-Ub or pNL-A1 plus pcDNA3.1-HA-Ub, and cultured for 48 h. Transfected cells were cultured in the presence of MG-132 (50 μ M) during the last incubation period, as indicated in the text. Cells were collected, lysed by TNE buffer (10 mM Tris-HCl pH 7.8, 0.15 M NaCl, 1 mM EDTA, 1% NP40, 10 μ g/ml of aprotinin) and immunoprecipitated with a polyclonal anti-Vif antibody (no. 2221 of NIH AIDS Research and Reference Reagent Program Catalog). The precipitated proteins were analyzed by western blotting using a monoclonal anti-HA antibody HA.11 (BabCO, Berkeley, CA, USA).

2.7. Reverse transcriptase (RT) assay

Virion-associated RT activity was determined as previously described [28].

3. Results

3.1. Vif is rapidly degraded by proteasomes in a cell-type-independent manner

Recent work by us has indicated that soluble cytosolic Vif is rapidly degraded in HeLa cells both in the absence and presence of APOBEC3G [20]. Extensive analysis of subcellular localization of Vif has demonstrated the existence of a soluble and a cytoskeletal form, and to a much lesser extent, the presence of a detergent-extractable form of Vif [29]. We first asked whether insoluble cytoskeletal Vif is unstable and whether the rapid degradation of Vif is generally observed in various cell types. We also asked whether the degradation can be blocked by proteasome inhibitors [30,31]. To address these questions, we performed pulse/chase and western blot analyses in transiently transfected 293T cells (Fig. 1). Vif was expressed from the subgenomic vector pNL-A1 [24], which is known to produce a high level of Vif upon transfection. Transfected 293T cells were labeled for 5 min with [³⁵S]-methionine and [³⁵S]-cysteine, chased for up to 60 min in the absence or presence of MG-132, and used for cell fractionation studies, as described in Section 2. As shown in Fig. 1A and B, while cytosolic Vif was degraded rapidly, cytoskeletal Vif was quite stable and accumulated with time. The proteasome inhibitor MG-132 blocked significantly the degradation of cytosolic Vif. This blocking effect was not observed for inhibitors of lysosome degradation (Bafilomycin A1 and EST) and calpain system (calpeptin) (data not shown). Accumulation of cytoskeletal Vif in cells was con-




Fig. 1. Stability analysis of HIV-1 Vif in 293T cells. (A) Stability of Vif in the absence or presence of proteasome inhibitor MG-132. 293T cells were transfected with 5 μ g of pNL-A1. Cells were collected 24 h after transfection, labeled for 5 min with [³⁵S]-methionine and [³⁵S]-cysteine, and chased for up to 60 min, as indicated above the lanes. Cells were incubated in the presence of MG132 (50 μ M) during the labeling and chasing time where indicated. Cell lysates were prepared as described in Section 2 and precipitated with a Vif-specific polyclonal antibody Vif93 [29]. Vif proteins were identified by SDS-PAGE followed by fluorography; sol: soluble fraction; insol: insoluble fraction. (B) Degradation kinetics of Vif. Vif-specific bands in (A) were quantified by scanning, and relative values were plotted as a function of time; (-), absence of MG-132; (+), presence of MG-132; total: sol plus insol. (C) Steady-state expression of Vif. 293T cells were transfected with 5 μ g of pNL-A1 (*vif*) or pUC19 (mock). Cells were harvested at 40 h post-transfection, and cell lysates were prepared as described in Section 2 for western blot analysis using an antibody Vif93. For sol-1, sol-2 and insol, see Section 2.

firmed by western blot analysis of transfected 293T cells at 40 h post-transfection (Fig. 1C). We extended these analyses to H9 and HeLa cells (Fig. 2). Transfected H9 and HeLa cells were pulse-labeled and chased as described above, and the degradation kinetics of two forms of Vif were monitored. As shown in Fig. 2, whereas Vif of a soluble form was degraded similarly rapidly, Vif of an insoluble form was quite stable and accumulated as observed in 293T cells.

Based on the effects of MG-132, Bafilomycin A1, EST, and calpeptin, we next assessed whether the ubiquitin-proteasome pathway was required for Vif degradation. Proteins that are selected for proteasomal degradation are marked by polyubiquitination (for review, see Refs. [32,33]). We con-




Fig. 2. Stability analysis of HIV-1 Vif in H9 and HeLa cells. Cells were transfected with 10 μ g of pNL-A1 plus 10 μ g of pNL432 (H9) or 5 μ g of pNL-A1 (HeLa). Cells were collected 24 h after transfection, labeled for 5 min with [³⁵S]-methionine and [³⁵S]-cysteine, and chased for up to 60 min, as indicated. Cell lysates were prepared as described in Section 2 and precipitated with a Vif-specific polyclonal antibody Vif93 [29]. Vif proteins were identified by SDS-PAGE followed by fluorography. Vif-specific bands were quantified by scanning, and relative values were plotted as a function of time; sol: soluble fraction; insol: insoluble fraction; total: sol plus insol.

transfected 293T cells with pNL-A1 and a vector that expresses HA-tagged ubiquitin, and the cells were analyzed by immunoprecipitation/western blot, as described in Section 2. As shown in Fig. 3, co-transfected cells contained large polyubiquitinated Vif proteins in amounts that were increased by prolonged incubation time with the proteasome inhibitor MG-132.

3.2. Formation of β -strand structures is important for regulated expression and function of Vif

We have recently shown that amino acid residues 88 and 89 in NL432 Vif are critical for steady-state expression of Vif and for viral infectivity [22]. The two residues are located within a β -strand structure (residues 86–89) as predicted by the PredictProtein (<http://www.embl-heidelberg.de/predictprotein/predictprotein.html>). We wanted to evaluate




Fig. 3. Ubiquitination of HIV-1 Vif. 293T cells were singly transfected with 3 μ g of pNL-A1 (Vif) or pcDNA3.1-HA-Ub (HA-Ub), or were double-transfected with pNL-A1 (1.5 μ g) plus pcDNA3.1-HA-Ub (1.5 μ g) (Vif + HA-Ub), and cultured for 48 h. Cells were cultured in the presence of MG-132 (50 μ M) during the last incubation period, as indicated above the lanes. Cell lysates were prepared, immunoprecipitated with a polyclonal anti-Vif antibody (NIH catalog no. 2221), and the precipitated proteins were analyzed by western blotting using a monoclonal anti-HA antibody HA.11 (BAbCO, Berkeley, CA, USA), as described in Section 2. (Ub)_n-Vif, polyubiquitinated Vif; Ub-Vif, monoubiquitinated Vif; IP:Vif, immunoprecipitation by anti-Vif antibody; Blot:HA, western blot analysis using anti-HA antibody.

the importance of the amino acids in this β -strand and in an adjacent one (residues 63–70) for Vif expression and for viral infectivity by deletion analysis (Fig. 4). Proviral deletion mutants designated pNL-fL64del, -fV65del, -fI66del, -fT67del, -fS86del and -fI87del were newly constructed from pNL432, as described in Section 2. Various proviral clones were transfected into 293T and H9 cells and monitored for expression of Vif and for viral infectivity, respectively. As shown in Fig. 4A, amino acids within the β -strand structures, but not those on the outside, were indispensable for normal expression of Vif in 293T cells. Growth potentials of the deletion mutants in H9 cells were then monitored. As shown in Fig. 4B, the mutants, which express Vif at a very low level in 293T cells, were not infectious for H9 cells. We then determined whether the observed low expression level of mutant Vif is due to rapid degradation rate. A pNL-A1 version of mutant Vif (pNL-A1-E88del) was constructed, and pulse/chase experiments using 293T cells were carried out, as described above. As can be clearly seen in Fig. 5A and B, E88del mutant Vif was more rapidly degraded than wt Vif. To ascertain the effect of proteasome inhibitors MG-132 and clasto-lactacystin β -lactone [30,31], steady-state levels of wt and mutant Vif proteins expressed by full-length proviral clones were determined in transfected 293T cells in the presence or absence of the inhibitors. As shown in Fig. 5C, E88del mutant Vif was expressed at a level similar to that of wt Vif only when the inhibitors were present.